Untreated metastatic or unresectable melanoma is an advanced skin cancer in which malignant melanocyte-derived cells have spread to distant sites or cannot be surgically removed. According to Mingyue Wang et al., 2025 data, an estimated 331,722 people were diagnosed with melanoma globally, and approximately 58,667 died from this disease. The pipeline for this indication features immunotherapies, targeted therapies, combination regimens, and novel cell- and gene-based approaches. According to the untreated metastatic or unresectable melanoma pipeline analysis by Expert Market Research, more than 100 drug candidates across multiple modalities and over 50 companies are involved, with major emphasis on biomarker-driven trials, resistance-management strategies, and expanding first-line indications. Topic-specific factors such as tumour heterogeneity, immune evasion, and regulatory convergence are expected to drive significant growth in the coming years.
Major companies involved in the untreated metastatic or unresectable melanoma pipeline analysis include IO Biotech, Merck Sharp & Dohme LLC, Syneos Health, and others.
Leading drugs currently in the pipeline include IO102-IO103, RO7247669, and others.
The pipeline growth is driven by advancements in immunotherapy combinations, increasing adoption of personalized medicine, and expanding research into novel targeted agents, enhancing treatment efficacy and patient outcomes.
The Untreated Metastatic or Unresectable Melanoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into untreated metastatic or unresectable melanoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for untreated metastatic or unresectable melanoma. The untreated metastatic or unresectable melanoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The untreated metastatic or unresectable melanoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with untreated metastatic or unresectable melanoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to untreated metastatic or unresectable melanoma.
Read more about this report - Request a Free Sample
Untreated metastatic or unresectable melanoma is an advanced and aggressive form of skin cancer that originates in melanocytes and spreads to distant organs, making surgical removal impossible. It develops due to genetic mutations, excessive ultraviolet radiation exposure, or immune dysregulation. Patients often experience fatigue, unexplained weight loss, swollen lymph nodes, or pain in affected areas.
Untreated metastatic or unresectable melanoma treatment involves immunotherapies, targeted therapies, and combination regimens designed to stimulate immune response and inhibit cancer cell growth, thereby prolonging survival and controlling disease progression. In May 2023, Opdualag (nivolumab and relatlimab-rmbw), developed by Bristol-Myers Squibb, emerged as a first-in-class dual immunotherapy in the metastatic or unresectable melanoma pipeline, enhancing T-cell activation and improving progression-free survival outcomes in clinical trials.
According to Mingyue Wang et al. (2025), 2022 data indicated that melanoma ranked as the 17th most common cancer worldwide, with approximately 331,722 new cases and 58,667 deaths reported globally. As per the Melanoma Research Alliance, around 104,960 new invasive melanoma cases are expected to be diagnosed in the United States in 2025, with nearly 8,430 deaths, including 5,470 men and 2,960 women. According to the British Dermatological Nursing Group, more than 100,000 new skin cancer cases are reported annually in the United Kingdom, and about two in three individuals experience a skin condition during their lifetime. As per Krishnan Sathishkumar et al. (2023), one in nine individuals in India is likely to develop cancer during their lifetime, emphasizing a growing healthcare concern.
This section of the report covers the analysis of untreated metastatic or unresectable melanoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The untreated metastatic or unresectable melanoma pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III at 67%, covers a major share of the total untreated metastatic or unresectable melanoma clinical trials. It is followed by phase II at 22% and phase I at 11%. The strong presence in advanced clinical phases reflects robust progress in drug development, positively influencing treatment prospects for untreated metastatic or unresectable melanoma.
The drug molecule categories covered under the untreated metastatic or unresectable melanoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides and polymers. The untreated metastatic or unresectable melanoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for untreated metastatic or unresectable melanoma. Immune checkpoint inhibitors and cellular-based therapies are key drug classes driving advancements in the untreated metastatic or unresectable melanoma pipeline. For example, pembrolizumab, a programmed death receptor-1 (PD-1) inhibitor, enhances immune response against tumor cells. Additionally, lifileucel, a Tumor Infiltrating Lymphocyte (TIL) therapy, is being evaluated in combination with pembrolizumab to improve response rates and overall survival outcomes.
The EMR report for the untreated metastatic or unresectable melanoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed untreated metastatic or unresectable melanoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in untreated metastatic or unresectable melanoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for untreated metastatic or unresectable melanoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of untreated metastatic or unresectable melanoma drug candidates.
IO102-IO103 is an investigational, off-the-shelf therapeutic cancer vaccine sponsored by IO Biotech. The ongoing Phase 3 clinical study aims to evaluate the efficacy and safety of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma. The study is examining progression-free survival as the primary endpoint. IO102-IO103 is designed to activate and expand T cells targeting IDO and PD-L1 positive cells, helping to destroy tumor and immune-suppressive cells within the tumor microenvironment.
RO7247669, developed by Hoffmann-La Roche, is a next-generation bispecific antibody being studied in a phase II trial for previously untreated unresectable or metastatic melanoma. This study is examining its efficacy, safety, pharmacokinetics, and pharmacodynamics to determine the recommended dose for future trials. RO7247669 works by simultaneously targeting PD-1 and LAG-3 proteins, key immune checkpoints that help cancer cells evade immune detection. By blocking these pathways, it enhances T-cell activation and anti-tumor response. The drug is administered through intravenous (IV) infusion at multiple dosing levels.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Untreated Metastatic or Unresectable Melanoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments untreated metastatic or unresectable melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into untreated metastatic or unresectable melanoma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share